万孚生物
(300482)
| 流通市值：79.91亿 | | | 总市值：86.97亿 |
| 流通股本：4.30亿 | | | 总股本：4.68亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 581,742,751.09 | 2,086,830,072.65 | 1,690,175,392.8 | 1,245,654,367.05 |
| 营业收入 | 581,742,751.09 | 2,086,830,072.65 | 1,690,175,392.8 | 1,245,654,367.05 |
| 利息收入 | - | - | 0 | - |
| 已赚保费 | - | - | 0 | - |
| 手续费及佣金收入 | - | - | 0 | - |
| 二、营业总成本 | 491,970,446.34 | 2,249,566,528.36 | 1,602,538,044.34 | 1,069,201,644.31 |
| 营业成本 | 213,831,615.49 | 897,853,120.8 | 671,032,425.44 | 462,548,481.08 |
| 利息支出 | - | - | 0 | - |
| 手续费及佣金支出 | - | - | 0 | - |
| 退保金 | - | - | 0 | - |
| 赔付支出净额 | - | - | 0 | - |
| 提取保险合同准备金净额 | - | - | 0 | - |
| 保单红利支出 | - | - | 0 | - |
| 分保费用 | - | - | 0 | - |
| 税金及附加 | 8,280,208.58 | 15,022,930.25 | 7,442,208.33 | 5,403,581.09 |
| 销售费用 | 137,420,185.44 | 658,840,553.03 | 484,552,232.7 | 318,913,059.05 |
| 管理费用 | 40,391,365.18 | 299,448,333.58 | 145,936,843.23 | 91,430,935.82 |
| 研发费用 | 73,647,885.55 | 336,700,613.8 | 265,096,901.5 | 174,217,875.75 |
| 财务费用 | 18,399,186.1 | 41,700,976.9 | 28,477,433.14 | 16,687,711.52 |
| 其中:利息费用 | 7,448,942.47 | 31,138,596.21 | 24,137,739.05 | 15,249,638.48 |
| 其中:利息收入 | 1,627,195.86 | 7,673,544.63 | 4,917,784.82 | 2,475,528.68 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 6,747,243.28 | 13,639,950.87 | 25,052,801.51 | 17,604,203.48 |
| 加:投资收益 | 3,137,777.57 | 39,786,048.52 | 13,744,980.69 | 9,519,032.06 |
| 净敞口套期收益 | - | - | 0 | - |
| 汇兑收益 | - | - | 0 | - |
| 资产处置收益 | - | 318,789.99 | 583.1 | -2,089.9 |
| 资产减值损失(新) | -1,000 | -23,709,931.39 | -7,835,193.97 | 4,207,021.92 |
| 信用减值损失(新) | -7,893,474.9 | -951,533.16 | -5,129,642.63 | -10,386,319.79 |
| 其他收益 | 6,154,805.59 | 23,237,287.78 | 16,273,070.84 | 10,447,058.09 |
| 四、营业利润 | 97,917,656.29 | -110,415,843.1 | 129,743,948 | 207,841,628.6 |
| 加:营业外收入 | 765,368.73 | 2,898,040.14 | 2,534,787.02 | 827,571.2 |
| 减:营业外支出 | 1,504,483.05 | 7,175,503.97 | 5,659,011.27 | 3,892,218.41 |
| 五、利润总额 | 97,178,541.97 | -114,693,306.93 | 126,619,723.75 | 204,776,981.39 |
| 减:所得税费用 | 11,056,073.74 | -45,034,833.47 | 184,947.97 | 14,567,109.49 |
| 六、净利润 | 86,122,468.23 | -69,658,473.46 | 126,434,775.78 | 190,209,871.9 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 86,122,468.23 | -69,588,874.23 | 126,434,775.78 | 190,209,871.9 |
| 终止经营净利润 | - | -69,599.23 | 0 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 84,399,549.76 | -63,024,899.74 | 133,739,825.24 | 189,198,935.53 |
| 少数股东损益 | 1,722,918.47 | -6,633,573.72 | -7,305,049.46 | 1,010,936.37 |
| 扣除非经常损益后的净利润 | 66,708,002.52 | -12,969,757.16 | 82,641,577.55 | 153,547,946.09 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.18 | -0.13 | 0.28 | 0.39 |
| (二)稀释每股收益 | 0.18 | -0.13 | 0.28 | 0.39 |
| 八、其他综合收益 | 18,116,871.33 | 42,498,484.27 | -66,202.61 | -37,344.56 |
| 归属于母公司股东的其他综合收益 | 18,116,871.33 | 42,498,484.27 | -66,202.61 | -37,344.56 |
| 九、综合收益总额 | 104,239,339.56 | -27,159,989.19 | 126,368,573.17 | 190,172,527.34 |
| 归属于母公司股东的综合收益总额 | 102,516,421.09 | -20,526,415.47 | 133,673,622.63 | 189,161,590.97 |
| 归属于少数股东的综合收益总额 | 1,722,918.47 | -6,633,573.72 | -7,305,049.46 | 1,010,936.37 |
| 公告日期 | 2026-04-23 | 2026-04-23 | 2025-10-27 | 2025-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |